Abeona Therapeutics Inc
ABEO6.425USD
-0.065-1.00%
시장 운영 시간 （ET）시세는 15분 지연됩니다
314.52M시가총액
손실P/E TTM
자세한 내용은 Abeona Therapeutics Inc 회사
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy Good Manufacturing Practice (cGMP) manufacturing facility served as the manufacturing site for pz-cel used in its Phase III VIITAL trial and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. The Company’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
회사 정보
종목 코드 ABEO
회사 이름Abeona Therapeutics Inc
상장일Sep 19, 1980
CEODr. Vishwas (Vish) Seshadri, Ph.D.
직원 수136
유형Ordinary Share
회계 연도 종료Sep 19
주소6555 Carnegie Ave, 4th Floor
도시CLEVELAND
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호44103
전화16468134701
웹사이트https://abeonatherapeutics.com/
종목 코드 ABEO
상장일Sep 19, 1980
CEODr. Vishwas (Vish) Seshadri, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
Dr. Bernhardt G. Zeiher, M.D.
Dr. Bernhardt G. Zeiher, M.D.
Independent Director
Independent Director
47.15K
--
Dr. Eric Crombez, M.D.
Dr. Eric Crombez, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph Vazzano, CPA
Mr. Joseph Vazzano, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Vishwas (Vish) Seshadri, Ph.D.
Dr. Vishwas (Vish) Seshadri, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.23M
-5.32%
Mr. Michael Amoroso
Mr. Michael Amoroso
Chairman of the Board
Chairman of the Board
180.47K
--
Dr. Leila Alland, M.D.
Dr. Leila Alland, M.D.
Independent Director
Independent Director
154.37K
--
Mr. Donald A. Wuchterl
Mr. Donald A. Wuchterl
Independent Director
Independent Director
145.44K
-3.44%
Ms. Christine Berni Silverstein
Ms. Christine Berni Silverstein
Independent Director
Independent Director
120.48K
-9.80%
Mr. Mark J. Alvino
Mr. Mark J. Alvino
Independent Director
Independent Director
77.34K
-14.48%
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Sat, Jul 12
마지막 업데이트: Sat, Jul 12
주주
주주 유형
주주
주주
비율
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
주주
주주
비율
Suvretta Capital Management, LLC
7.20%
Nantahala Capital Management, LLC
6.86%
Adage Capital Management, L.P.
5.26%
Western Standard, LLC
4.46%
The Vanguard Group, Inc.
3.95%
Other
72.27%
주주 유형
주주
비율
Hedge Fund
39.27%
Investment Advisor
9.65%
Investment Advisor/Hedge Fund
6.04%
Individual Investor
5.83%
Venture Capital
4.82%
Research Firm
3.12%
Pension Fund
0.17%
Other
31.08%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
154
35.41M
69.26%
-4.09M
2025Q1
147
35.53M
69.67%
-3.94M
2024Q4
142
35.48M
81.61%
-1.29M
2024Q3
136
33.53M
77.24%
-4.39M
2024Q2
136
35.81M
86.04%
+12.73M
2024Q1
132
18.43M
63.48%
+1.42M
2023Q4
122
17.76M
63.56%
+2.13M
2023Q3
129
13.60M
55.05%
-1.35M
2023Q2
141
10.67M
49.73%
+4.50K
2023Q1
170
7.90M
44.30%
-1.15M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Suvretta Capital Management, LLC
3.69M
7.2%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.51M
6.86%
-19.36K
-0.55%
Mar 31, 2025
Adage Capital Management, L.P.
2.69M
5.26%
-1.21M
-31.03%
Mar 31, 2025
Western Standard, LLC
2.28M
4.46%
+196.78K
+9.44%
Mar 31, 2025
The Vanguard Group, Inc.
2.02M
3.95%
+54.16K
+2.75%
Mar 31, 2025
Vivo Capital, LLC
1.84M
3.6%
--
--
Mar 31, 2025
Rosalind Advisors, Inc.
1.81M
3.53%
+427.00
+0.02%
Mar 31, 2025
Laurion Capital Management LP
1.31M
2.55%
--
--
Mar 31, 2025
Armistice Capital LLC
1.30M
2.54%
+1.30M
--
Dec 31, 2023
Seshadri (Vishwas)
1.30M
2.55%
-51.56K
-3.80%
Jun 06, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Simplify Propel Opportunities ETF
4.69%
iShares Neuroscience and Healthcare ETF
0.63%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
더 보기
Simplify Propel Opportunities ETF
비율4.69%
iShares Neuroscience and Healthcare ETF
비율0.63%
iShares Micro-Cap ETF
비율0.06%
iShares Russell 2000 Growth ETF
비율0.02%
Proshares Ultra Russell 2000
비율0.01%
ProShares Hedge Replication ETF
비율0.01%
ProShares UltraPro Russell2000
비율0.01%
iShares Russell 2000 ETF
비율0.01%
Global X Russell 2000 ETF
비율0.01%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
날짜
유형
비율
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
Jul 01, 2022
Merger
25<1
